Janux Therapeutics, Inc. $JANX Shares Purchased by FNY Investment Advisers LLC

FNY Investment Advisers LLC increased its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 111.8% during the 2nd quarter, Holdings Channel.com reports. The fund owned 5,210 shares of the company’s stock after purchasing an additional 2,750 shares during the quarter. FNY Investment Advisers LLC’s holdings in Janux Therapeutics were worth $120,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in Janux Therapeutics by 1,574.0% during the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company’s stock worth $45,000 after acquiring an additional 1,574 shares in the last quarter. US Bancorp DE raised its stake in Janux Therapeutics by 2,402.9% during the 1st quarter. US Bancorp DE now owns 1,727 shares of the company’s stock worth $47,000 after acquiring an additional 1,658 shares in the last quarter. KBC Group NV acquired a new stake in Janux Therapeutics during the 1st quarter worth $66,000. Exchange Traded Concepts LLC raised its stake in Janux Therapeutics by 20.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 4,043 shares of the company’s stock worth $109,000 after acquiring an additional 686 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Janux Therapeutics by 26.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,125 shares of the company’s stock worth $192,000 after acquiring an additional 1,488 shares in the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Stock Down 1.8%

Shares of Janux Therapeutics stock opened at $26.34 on Thursday. Janux Therapeutics, Inc. has a 52-week low of $21.73 and a 52-week high of $71.71. The company’s 50-day simple moving average is $24.32 and its 200-day simple moving average is $25.29. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of -14.63 and a beta of 2.82.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.07). Equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Barclays assumed coverage on shares of Janux Therapeutics in a research note on Wednesday, September 17th. They issued an “overweight” rating and a $47.00 price objective on the stock. Truist Financial assumed coverage on shares of Janux Therapeutics in a research note on Wednesday, September 10th. They issued a “buy” rating and a $100.00 price objective on the stock. Piper Sandler assumed coverage on shares of Janux Therapeutics in a research note on Monday, August 18th. They issued an “overweight” rating and a $42.00 price objective on the stock. Raymond James Financial assumed coverage on shares of Janux Therapeutics in a research note on Friday, July 11th. They issued an “outperform” rating and a $65.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $78.31.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.